Atdose

Atdose, founded in Yokohama, Japan on September 1, 2017, by Hidenori Nakamura, is developing a novel drug delivery platform. The company's core patented technology is the Electro-Osmotic Pump (EO pump), a mobile-type infusion device engineered to administer ultra-small, continuous, and localized doses of medication directly to an affected area. This technology is designed to handle highly viscous liquids even with thin needles, which is challenging with manual methods.

The business model focuses on collaborating with pharmaceutical companies and researchers by providing customized dosing devices for research and testing. Atdose is actively seeking partnerships with medical device manufacturers for future product development. The company targets several medical fields, with initial research focusing on ophthalmology—specifically for Micro-Incision Vitrectomy Surgery (MIVS)—and oncology. The technology also shows promise for regenerative medicine by enabling the precise delivery of cells and in gene therapy, where targeted administration is critical. The company has established a presence in India with the incorporation of ATDOSE INDIA PRIVATE LIMITED in August 2022.

Keywords: drug delivery system, electro-osmotic pump, micro-dosing, localized drug delivery, ophthalmology, vitrectomy, MIVS, regenerative medicine, oncology, gene therapy, infusion device, medical device, pharmaceutical technology, controlled release, IoMT